<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632940</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-3019-094</org_study_id>
    <nct_id>NCT04632940</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with&#xD;
      systemic corticosteroids administered every two weeks in ambulatory subjects with Duchenne&#xD;
      muscular dystrophy (age 6 to &lt;12 years).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global, randomized, double-blind, trial of pamrevlumab or placebo in combination&#xD;
      with systemic corticosteroids in subjects with Duchenne muscular dystrophy, aged 6 to &lt;12&#xD;
      years (ambulatory subjects only). Approximately 70 subjects will be randomized at a 1:1 ratio&#xD;
      to Arm A (pamrevlumab + systemic deflazacort or equivalent potency of corticosteroids&#xD;
      administered orally) or Arm B (placebo+ systemic deflazacort or equivalent potency of&#xD;
      corticosteroids administered orally), respectively.&#xD;
&#xD;
      Subjects must be fully informed of the potential benefits of approved products and make an&#xD;
      informed decision when participating in a clinical trial in which they could be randomized to&#xD;
      placebo.&#xD;
&#xD;
      Subjects will be randomized in a 1:1 ratio to one of the two study treatment arms;&#xD;
      pamrevlumab or placebo. Randomization will be stratified by exon 44 deletion.&#xD;
&#xD;
      The main study has three study periods:&#xD;
&#xD;
        -  Screening period: Up to 4 weeks&#xD;
&#xD;
        -  Treatment period: 52 weeks&#xD;
&#xD;
        -  Safety Follow-up period/final assessment: A visit 28 days (+/- 3 Days) and a final&#xD;
           safety follow-up phone call 60 days (+ 3 Days) after the last dose&#xD;
&#xD;
      Each subject will receive pamrevlumab or placebo at 35 mg/kg every 2 weeks for up to 52&#xD;
      weeks. Subjects who complete 52 weeks of treatment may be eligible for an open-label&#xD;
      extension (OLE), offering extended treatment with pamrevlumab.&#xD;
&#xD;
      Subjects who discontinue study treatment for any reason should be encouraged to return to the&#xD;
      investigative site to complete final safety and efficacy assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory function assessment:</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Change in NorthStar Ambulatory Assessment (NSAA) Linearized total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other Muscle function assessments:</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Change in 4-stair climb Velocity (4SCV) assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Muscle function assessments:</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Change in the 10-meter walk/run test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Muscle function assessments:</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Changes in Time to Stand (TTSTAND)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Muscle function assessments:</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Time to Loss of Ambulation (LoA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamrevlumab</intervention_name>
    <description>pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>FG-3019</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age, and consent:&#xD;
&#xD;
          1. Males at least 6 to &lt;12 years of age at screening initiation&#xD;
&#xD;
          2. Written consent by legal guardian as per regional/ country and/or IRB/IEC requirements&#xD;
&#xD;
             DMD diagnosis:&#xD;
&#xD;
          3. Medical history includes diagnosis of DMD and confirmed Duchenne mutation using a&#xD;
             validated genetic test.&#xD;
&#xD;
             Pulmonary criteria:&#xD;
&#xD;
          4. Average (of screening and day 0) percent predicted FVC above 45%&#xD;
&#xD;
          5. On a stable dose of systemic corticosteroids for a minimum of 6 months, with no&#xD;
             substantial change in dosage for a minimum of 3 months (except for adjustments for&#xD;
             changes in body weight) prior to screening. Corticosteroid dosage should be in&#xD;
             compliance with the DMD Care Considerations Working Group recommendations (e.g.&#xD;
             prednisone or prednisolone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day) or&#xD;
             stable dose. A reasonable expectation is that dosage and dosing regimen would not&#xD;
             change significantly for the duration of the study.&#xD;
&#xD;
             Performance criteria:&#xD;
&#xD;
          6. Able to complete 6MWD test with a distance of at least 270M but no more than 450M on&#xD;
             two occasions within 3 months prior to Randomization with ≤10% variation between these&#xD;
             two tests.&#xD;
&#xD;
          7. Able to rise (TTSTAND) from floor in &lt;10 seconds (without aids/orthoses) at screening&#xD;
             visit.&#xD;
&#xD;
          8. Able to undergo MRI test for the lower extremities vastus lateralis muscle.&#xD;
&#xD;
             Vaccination:&#xD;
&#xD;
          9. Received pneumococcal vaccine (PPSV23) (or any other pneumococcal polysaccharide&#xD;
             vaccine as per national recommendations) and is receiving annual influenza&#xD;
             vaccinations.&#xD;
&#xD;
             Laboratory criteria:&#xD;
&#xD;
         10. Adequate renal function: cystatin C ≤1.4 mg/L&#xD;
&#xD;
         11. Adequate hematology and electrolytes parameters:&#xD;
&#xD;
               1. Platelets &gt;100,000/mcL&#xD;
&#xD;
               2. Hemoglobin &gt;12 g/dL&#xD;
&#xD;
               3. Absolute neutrophil count &gt;1500 /μL&#xD;
&#xD;
               4. Serum calcium (Ca), potassium (K), sodium (Na), magnesium (Mg) and phosphorus (P)&#xD;
                  levels are within a clinically accepted range&#xD;
&#xD;
         12. Adequate hepatic function:&#xD;
&#xD;
               1. No history or evidence of liver disease&#xD;
&#xD;
               2. Gamma glutamyl transferase (GGT) ≤3x upper limit of normal (ULN)&#xD;
&#xD;
               3. Total bilirubin ≤1.5xULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Criteria:&#xD;
&#xD;
          1. Concurrent illness other than DMD that can cause muscle weakness and/or impairment of&#xD;
             motor function&#xD;
&#xD;
          2. Severe intellectual impairment (eg, severe autism, severe cognitive impairment, severe&#xD;
             behavioral disturbances) preventing the ability to perform study assessments in the&#xD;
             Investigator's judgment&#xD;
&#xD;
          3. Previous exposure to pamrevlumab&#xD;
&#xD;
          4. BMI ≥40 kg/m2 or weight &gt;117 kg&#xD;
&#xD;
          5. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine&#xD;
             monoclonal antibodies&#xD;
&#xD;
          6. Exposure to any investigational drug (for DMD or not), in the 30 days prior to&#xD;
             screening initiation or use of approved DMD therapies (e.g., eteplirsen, ataluren,&#xD;
             golodirsen) within 5 half-lives of screening, whichever is longer with the exception&#xD;
             of the systemic corticosteroids, including deflazacort&#xD;
&#xD;
             Pulmonary and Cardiac criteria:&#xD;
&#xD;
          7. Requires ≥16 hours continuous ventilation&#xD;
&#xD;
          8. Poorly controlled asthma or underlying lung disease such as bronchitis,&#xD;
             bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the investigator&#xD;
             might impact respiratory function&#xD;
&#xD;
          9. Hospitalization due to respiratory failure within the 8 weeks prior to screening&#xD;
&#xD;
         10. Severe uncontrolled heart failure (NYHA Classes III-IV), including any of the&#xD;
             following:&#xD;
&#xD;
               1. Need for intravenous diuretics or inotropic support within 8 weeks prior to&#xD;
                  screening&#xD;
&#xD;
               2. Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks&#xD;
                  prior to screening&#xD;
&#xD;
         11. Arrhythmia requiring anti-arrhythmic therapy&#xD;
&#xD;
         12. Any other evidence of clinically significant structural or functional heart&#xD;
             abnormality&#xD;
&#xD;
             Clinical judgment:&#xD;
&#xD;
         13. The Investigator judges that the subject will be unable to fully participate in the&#xD;
             study and complete it for any reason, including inability to comply with study&#xD;
             procedures and treatment, or any other relevant medical, surgical or psychiatric&#xD;
             conditions&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Charpentier</last_name>
    <phone>415.978.1346</phone>
    <email>LELANTOS@fibrogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aravindhan Veerapandiyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leigh Maria Ramos-Platt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Children's Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Craig McDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barry Byrne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anthony Giordano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Han Phan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vamshi Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Mathews</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Statland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Doris Leung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brenda Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erin Knierbein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jena Krueger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Zaidman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cuixia Tian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Finanger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ashutosh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Brandsema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Burnette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Farida Abid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Russell Butterfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Crystal Proud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seth Perlman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Monique Ryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maina Kava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Favoriten</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Günther Bernert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liesbeth De Waele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional de la Citadelle</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphanie Delstanche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Deconinck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kathryn Selby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Laugel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yann Pereon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Association Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvana De Lucia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRRCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stefano Previtali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricovero e Cura a Carattere Scientifico Eugenio Medea - Lombardia</name>
      <address>
        <city>Bosisio ParIni</city>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Grazia D'Angelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NeMO</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valeria Sansone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eugenio Maria Mercuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - Roma - Gianicolo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adele D'Amico</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Niks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Saskia Houwen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Gomez-Andrés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nuria Muelas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust</name>
      <address>
        <city>Gobowen</city>
        <state>England</state>
        <zip>SY10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tracey Willis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Marie Childs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stefan Spinty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and Saint Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vasantha Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sithara Ramdas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Min Ong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy, DMD</keyword>
  <keyword>Muscular Dystrophies</keyword>
  <keyword>Muscular Dystrophy, Duchenne</keyword>
  <keyword>Muscular Disorders, Atrophic</keyword>
  <keyword>Muscular Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Genetic Diseases, X-Linked</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

